Omadacycline: Phase III data

Top-line data from the modified intent-to-treat (mITT) population of the double-blind, international Phase III OASIS trial in 645 patients with ABSSSIs showed that once-daily IV-to-oral

Read the full 252 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE